Salute e Benessere
DeuterOncology to Present Promising Phase I DO-2 MET Kinase Inhibitor Data at WCLC 2025
"These results represent a significant advancement in MET-targeted therapy," . "Our deuteration strategy has successfully enhanced drug exposure while maintaining efficacy, but most importantly, we have achieved this without the debilitating peripheral oedema that forces many patients to discontinue current MET inhibitors —symptoms that can severely limit daily activities such as walking, dressing, or cooking. This addresses a critical unmet medical need for cancer patients."
"The clinical data for DO-2 are very encouraging. The fact that we're seeing robust anti-tumor activity with minimal peripheral oedema represents a potential game-changer for MET-driven lung cancer patients, who currently face difficult treatment tolerability issues with existing therapies."
The study confirms DeuterOncology's hypothesis that continuous 24/7 MET inhibition is not required for efficacy but is responsible for the class-effect toxicity of peripheral oedema. DO-2's unique biochemical and pharmacokinetic profile allows for effective target engagement while providing recovery periods that minimize on-target toxicities.
Based on these promising Phase I results, DeuterOncology has initiated an expansion cohort in selected first-line MET exon 14 skip NSCLC patients to further validate the safety and efficacy of the 60mg once-daily regimen.
Preliminary Safety and PK of the MET-TKI DO-2 in Advanced Solid Tumors with MET Aberrations: Phase I Study
Authors: Hans Prenen MD, PhD, Rachel Galot MD, PhD, Alexis Cortot MD, PhD, Aurélie Swalduz MD, PhD, Bernd Dekeyser MD, Peter de Bruijn PhD, Francois Zammit MD, Jean-Pascal Machiels MD, PhD, Brant Delafontaine MD, Sylvie Rottey MD, PhD, Ingrid Desar MD, PhD, Marthe Paats MD, PhD, Barend J. Sikkema MD, , Florence Wastelin MSc, Cecilia Ahlin MD PhD, Timothy Perera PhD , Jaap Verweij MD, PhD, Carla van Herpen MD, PhD, Debbie G.J. Robbrecht MD, PhD
: Timothy Perera
: 09 September 2025 . 10.00AM CEST
Abstract ID-2859. P3.18.66
Lung cancer remains the most common form of cancer worldwide, affecting approximately 2.2 million individuals annually. MET exon 14 skipping mutations occur in ~3% of NSCLC patients—equating to an estimated 60,000–70,000 new cases worldwide annually—and represent a validated therapeutic target. However, current approved MET inhibitors suffer from high rates of peripheral oedema (>50% of patients), leading to frequent dose reductions, treatment interruptions, and discontinuations that compromise patient outcomes.
DeuterOncology is a clinical-stage biotech company focused on developing deuterated kinase inhibitors as best-in-class targeted cancer therapies. The company's lead candidate, DO-2, is a novel deuterated MET kinase inhibitor designed to overcome the tolerability limitations of current MET-targeted therapies while maintaining superior efficacy. Headquartered in Liège, Belgium , DeuterOncology was founded in 2020 by Dr. Timothy Perera and collaborates with a global expert network of partners to bring innovative cancer solutions to patients worldwide.
For more information about DeuterOncology's research, please visit www.deuteroncology.com
View original content:https://www.prnewswire.co.uk/news-releases/deuteroncology-to-present-promising-phase-i-do-2-met-kinase-inhibitor-data-at-wclc-2025-302549690.html